
Dupixent CTCL Lawsuits: The Next Emerging MDL
Plaintiffs are moving to centralize Dupixent cutaneous T-cell lymphoma cases as an MDL after the FDA flagged a safety signal.
7 articles with this tag

Plaintiffs are moving to centralize Dupixent cutaneous T-cell lymphoma cases as an MDL after the FDA flagged a safety signal.


The first formula-linked infant botulism outbreak—48 cases across 19 states—is now a federal MDL in New York.

BD's $1B+ Bard hernia mesh settlement uses a tiered system where documentation quality determines whether claimants receive $2,500 or $100,000+.



Latest Camp Lejeune litigation updates including court rulings, settlement progress, and how law firms are tackling the critical medical records challenge with nearly 500,000 claims filed.